ABL Bio
ABL Bio is a biotech company in Seongnam, South Korea, founded in 2016.
Pioneering bispecific antibodies for oncology and neurodegenerative diseases
- Headquarters
- Seongnam
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- ablbio.com
About
ABL Bio is a South Korean research-led biotechnology company and pioneer in bispecific antibodies, with programs spanning immuno-oncology, neurodegenerative diseases, and antibody-drug conjugates. Founded in 2016 by Sang Hoon Lee and listed on the KOSDAQ exchange (298380), the company develops novel therapeutic platforms that address high unmet medical needs by combining bispecific antibody expertise with innovative drug delivery approaches. ABL Bio collaborates with global partners to advance its pipeline — which includes programs such as ABL301 for Parkinson's disease and ABL503 for solid tumors — and in 2025 established NEOK Bio in California with $75 million from Blackstone Life Sciences to advance two bispecific ADCs in the US market.
Summary
It lists 51–200 employees.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/abl-bio"><img src="https://indexed.vc/api/badge/company/abl-bio" alt="ABL Bio on Indexed.vc" width="260" height="76" /></a>